UK Spinal Muscular Atrophy Payer & HTA

NICE initially rejected Zolgensma (onasemnogene abeparvovec) under its Highly Specialised Technologies (HST) route in 2021 (HST15), when its cost per QALY exceeded £200,000 at a WAC of $2.125M (approximately £1.8M) without adequate discount. Novartis returned in 2022 with a Commercial Access Agreement / Patient Access Scheme, and NICE applied its Long-Term Value Framework (LTVF) — a methodology permitting cost-effectiveness modelling beyond the standard 30-year horizon in recognition of gene therapy's potentially curative effect. NICE HST24 (2023) accepted the revised submission, with a Managed Access Agreement requiring two years of real-world outcome data collection across 6 NHS gene therapy centres for approximately 50-60 annual UK cases. Critically, NICE's modelling found that newborn-screening-identified pre-symptomatic infants (drawing on the NURTURE trial cohort) generate a materially higher QALY gain from Zolgensma than symptomatic Type 1 infants, strengthening the health economic case specifically for the pre-symptomatic population NBS identifies.

For older SMA patients, chronic therapy remains the NHS standard: nusinersen (Spinraza), NICE TA588 (2019) with PAS, costs an estimated £150,000-£250,000 per year in maintenance (loading year costs £500,000-£700,000) across roughly 300 UK Type 2/3 patients, while risdiplam runs an estimated £100,000-£200,000 per year. Combined NHS chronic SMA therapy spend across both agents is estimated at £45-75M annually. NICE's own break-even modelling makes the underlying economic logic explicit: for a newborn-screening-identified infant, one-time Zolgensma at an estimated PAS net cost of £1.2-1.6M compares against a lifelong chronic therapy cost of £4.5-7.5M (£150,000-250,000/year over 30-plus years) — meaning gene therapy is cost-effective under the NHS QALY model at PAS pricing, a fundamentally different economic dynamic than any rare disease market without a gene therapy option.

This assessment is built from NICE Highly Specialised Technology and Technology Appraisal documentation (HST24, HST15, TA588), NICE's Long-Term Value Framework methodology papers, and NHS England SMA commissioning budget data.

Key sources: NICE HST24 (2023) Final Evaluation Determination and HST15 (2021) rejection record; NICE TA588 (nusinersen, 2019); NICE Long-Term Value Framework (LTVF) SMA analysis; NHS England SMA commissioning budget analysis.